BOCA RATON, FL, UNITED STATES, June 16, 2026 /EINPresswire.com/ -- Baker Legal Team today announced the launch of ...

The frontMIND study adds two immune‑based medicines (tafasitamab and lenalidomide) to standard R‑CHOP, a type of chemotherapy ...

It develops from the abnormal multiplication of T cells, or T-lymphocytes, a type of white blood cell essential for immune system function. The specific treatment course and prognosis for T-cell ...

Filing acceptance based on data from the phase III SUNMO study where subcutaneous Lunsumio VELO plus Polivy demonstrated a 59% reduction in risk of disease progression or death1 People with relapsed ...

T, has transformed treatment for blood cancers. The immunotherapy involves reprogramming a patient's own immune cells to ...

In the largest study of its kind, researchers from The University of Texas MD Anderson Cancer Center identified three subgroups of patients with large B-cell lymphoma (LBCL) who have different levels ...

Scientists at Florida International University may have found a way to make a powerful cancer treatment work even better. The ...

Incyte Biosciences Japan G.K. today announced that Japan’s Ministry of Health, Labour and Welfare (MHLW) has approved Minjuvi ® (tafasitamab) in combination with lenalidomide for the treatment of ...

B-cell lymphoma is a type of non-Hodgkin lymphoma. It’s also the most common type of lymphoma. Approximately 85% of all lymphomas in the United States are B-cell lymphomas. Non-Hodgkin lymphomas are ...

It’s like “Rituxan all over again,” said CEO Richard Miller, who believes Corvus’ lead candidate could make an impact in both ...